Christchurch, New Zealand, May 23, 2008
ARANZ Medical Limited, a leading innovator in wound assessment technology, announces that its ARANZ Medical Silhouette™ product suite has recently received both Therapeutic Goods Administration (TGA) and Canadian Ministry of Health approval. With these certifications, ARANZ Medical is now able to market Silhouette, an efficient solution for collection of wound data, within both Australia and Canada.
The ARANZ Medical Silhouette product suite represents a significant advance in the management of patients with skin wounds. With the aging population and rising prevalence of diabetes the incidence of wounds is increasing. As opposed to the largely ad hoc methods that have been used to track wound healing progress to date, Silhouette provides a very efficient, integrated, non-contact, and repeatable solution for collecting information about wounds.
Australian and Canadian approval adds to the already received FDA approval and CE Marking allowing Silhouette to be sold in many countries, particularly the US, Europe, Canada, Australia and New Zealand.
“The Silhouette suite of products is an innovative concept that is improving wound care practice,” says Dr Mark Nixon, Chief Medical Officer at ARANZ Medical Limited. “Over the last 3 years we realized that a better solution could be developed that could be more accurate, more efficient, and more integrated than the currently employed methods. Working closely with wound care professionals we have developed the Silhouette product suite which has received enthusiastic reviews from wound care professionals on several continents.”
Silhouette has successfully been trialled in Australia. The Royal District Nursing Service (RDNS) in Melbourne is a site for a current Proof of Concept trial of the Silhouette suite in a District and Home Care nursing environment.
“Receiving Australian and Canadian regulatory approvals for Silhouette are two more notable milestones for ARANZ Medical,” reports Bruce Davey PhD, CEO of ARANZ Medical. “With Silhouette’s significant advantages for all participants in the wound care process including patients, nurses, physicians, wound care centres, district nursing agencies, home health providers and researchers, we believe that Silhouette will find wide appeal with wound care professionals. We are delighted that Silhouette is now available to assist Australian and Canadian researchers and health care professionals provide superior care for their patients.”
The ARANZ Medical Silhouette is available for sale in both Australia and Canada. Additional information can be found on the ARANZ Medical Web Site, www.aranzmedical.com.